Santen is a Japanese pharmaceutical company specializing in the development and manufacturing of ophthalmic products.
Business Model:
Revenue: $0
Employees: 1,001-5,000
Santen USA was acquired by
Unison Capital.
The acquisition happend on 2015-08-16.
Details of the transaction were not public
Address: 6401 Hollis Street,
City: Emeryville
State: CA
Zip: 94608
Country: US
At Santen, they’re innovating therapies to improve the quality of life for patients worldwide. Their single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a globally competitive company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Their clinical development network now spans three continents, with centers in Europe, Japan, and the United States.
Contact Phone:
+14152689100
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
11/2015 | RetroSense Therapeutics | Series B | 0 |
12/2015 | InnFocus Inc | Series C | 0 |
11/2015 | TearSolutions | Series A | 0 |
8/2016 | International Biomedical Devices | Debt Financing | 0 |
10/2017 | QD Laser, Inc. | Venture Round | 0 |
8/2018 | QD Laser, Inc. | Series F | 0 |
7/2020 | Plano | Corporate Round | - |
2/2013 | Clearside Biomedical | Series A | 7.9M |
9/2014 | Clearside Biomedical | Series B | 16M |
7/2020 | Plano | Corporate Round | - |
8/2018 | QD Laser, Inc. | Series F | 0 |
10/2017 | QD Laser, Inc. | Venture Round | 0 |
8/2016 | International Biomedical Devices | Debt Financing | 0 |
12/2015 | InnFocus Inc | Series C | 0 |
11/2015 | RetroSense Therapeutics | Series B | 0 |
11/2015 | TearSolutions | Series A | 0 |
9/2014 | Clearside Biomedical | Series B | 0 |
2/2013 | Clearside Biomedical | Series A | 0 |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2009 | Post-IPO Equity | 7 | $22M |
Omnes Capital 123Venture Bpifrance Andera Partners Auriga Partners Idinvest Partners Innovation Capital Omnes Capital 123Venture Bpifrance Andera Partners Auriga Partners Idinvest Partners Innovation Capital |
4/2006 | Post-IPO Equity | 6 | $31.5M |
Andera Partners Omnes Capital 123Venture Innovation Capital Bpifrance Auriga Partners Andera Partners Omnes Capital 123Venture |
11/2003 | Post-IPO Equity | 5 | $5.8M |
Omnes Capital Innovation Capital Bpifrance Auriga Partners 123Venture |
9/2004 | Post-IPO Equity | 5 | $11.2M |
Siparex Groupe Innovation Capital Bpifrance Auriga Partners Andera Partners |
1/2000 | Post-IPO Equity | 2 | $3.8M |
Innovation Capital Auriga Partners |
---|
Announced Date | Name | Price |
---|---|---|
9/2020 | Eyevance Pharmaceuticals | |
7/2016 | InnFocus Inc |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|